MedTrace Logo

Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

NCT00324038 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2011-06-14

Study results available
· View outcomes & findings →

Summary

The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).

Conditions

Interventions

DRUG

Buprenorphine

buprenorphine transdermal system 5, 10 and 20 mg

DRUG

Codeine paracetamol

combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500

Sponsors & Collaborators

  • Napp Pharmaceuticals Limited

    lead INDUSTRY

Principal Investigators

  • Prof Philip Conaghan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2007-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00324038 on ClinicalTrials.gov